You are using an older version of Internet Explorer that is not supported on this site. Please upgrade for the best experience.

Watchman Left Atrial Appendage Closure Device

Baystate Interventional Cardiology now implants the Watchman, Left Atrial Appendage Closure Device, a first-of-its-kind, proven alternative to long-term warfarin therapy for stroke risk reduction in patients with non-Valvular atrial fibrillation (AF).

The Watchman Device is intended for percutaneous, transcatheter closure of the of the left atrial appendage (LAA).  By closing off the LAA, a thin, sack-like appendix arising from the left side of the heart that is believed to be the source of the majority of stroke-causing blood clots in people with non-Valvular AF1, the risk of stroke may be reduced and, over time, patients may be able to stop taking warfarin. 

Who is appropriate for Watchman? 

Patients who may be eligible: 

  • Are at an increased risk for stroke and systemic embolism based on CHADS2 or CHAD2DS2-VAScscores and are recommended for anticoagulation therapy
  • Are deemed by their physicians to be suitable for warfarin
  • Have an appropriate rationale to seek non-pharmacologic alternative to warfarin, taking into account the safety and effectiveness of the device compared to warfarin. 

Refer a patient: 413-794-4011